IMVT Stock Analysis: Immunovant | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.911m USD | 12M Return: 130.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 53.1M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Immunovant, Inc. is a clinical-stage immunology company developing monoclonal antibody therapies for autoimmune diseases. Its lead candidate, IMVT-1402, inhibits the neonatal Fc receptor and is being studied for conditions including Graves disease, rheumatoid arthritis, Sjögrens disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Founded in 2018 and based in Durham, North Carolina, Immunovant operates as a subsidiary of Roivant Sciences Ltd., which uses a hub-and-spoke model in which dedicated biotech entities are formed around individual therapeutic programs. As a clinical-stage company with no approved products, Immunovants value is tied to pipeline and clinical-trial outcomes rather than commercial revenue.
- IMVT-1402 phase 3 trial readouts approach across autoimmune indications
- Cash runway supports pipeline advancement through key catalysts
- Competition intensifies from argenxs Vyvgart in FcRn inhibitor market
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA 5.96 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.43 > 3% & CFO -407.3m > Net Income -505.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (203.7m) vs 12m ago 34.40% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 948.8m - Total Current Liabilities 104.4m) / Total Assets 957.0m |
| B: -1.82 (Retained Earnings -1.75b / Total Assets 957.0m) |
| C: -0.58 (EBIT TTM -505.4m / Avg Total Assets 866.6m) |
| D: 8.16 (Book Value of Equity 852.6m / Total Liabilities 104.4m) |
| Altman-Z'' = 4.50 = AA |
As of July 03, 2026, the stock is trading at USD 38.79 with a total of 1,036,211 shares traded. Over the past week, the price has changed by +1.44%, over one month by +25.45%, over three months by +58.33% and over the past year by +130.76%.
Current recommended Stop Loss: 36.90 (which is 4.9% or 1.2 ATR below the current price).
Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 45.8 | 18% |
P/B = 9.1843
Revenue TTM = 0.0 USD
EBIT TTM = -505.4m USD
EBITDA TTM = -505.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 72.0k USD (from shortTermDebt, last quarter)
Debt = 72.0k USD (from shortLongTermDebtTotal, last quarter) (leases 72.0k already included)
Net Debt = -902.0m USD (calculated: Debt 72.0k - CCE 902.1m)
Enterprise Value = 7.01b USD (7.91b + Debt 72.0k - CCE 902.1m)
Interest Coverage Ratio = unknown (Ebit TTM -505.4m / Interest Expense TTM 0.0)
EV/FCF = -17.21x (Enterprise Value 7.01b / FCF TTM -407.3m)
FCF Yield = -5.81% (FCF TTM -407.3m / Enterprise Value 7.01b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 409k) / Revenue TTM)
Tobins Q-Ratio = 7.32 (Enterprise Value 7.01b / Total Assets 957.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -399.3m (EBIT -505.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.09 (Total Current Assets 948.8m / Total Current Liabilities 104.4m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 852.6m)
Debt / EBITDA = 1.79 (negative EBITDA) (Net Debt -902.0m / EBITDA -505.0m)
Debt / FCF = 2.21 (negative FCF - burning cash) (Net Debt -902.0m / FCF TTM -407.3m)
Total Stockholder Equity = 741.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.34% (Net Income -505.6m / Total Assets 957.0m)
RoE = -68.16% (Net Income TTM -505.6m / Total Stockholder Equity 741.7m)
RoCE = -68.14% (EBIT -505.4m / Capital Employed (Equity 741.7m + L.T.Debt 0.0))
RoIC = -46.82% (negative operating profit) (NOPAT -399.3m / Invested Capital 852.7m)
WACC = 9.87% (E(7.91b)/V(7.91b) * Re(9.87%) + D(72.0k)/V(7.91b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 16.48%
[DCF] Fair Price = unknown (Cash Flow -407.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.41 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.53 | Chg30d=+45.23% | Revisions=+20% | Analysts=1
EPS current Year (2027-03-31): EPS=-2.44 | Chg30d=+5.40% | Revisions=-14% | GrowthEPS=+0.9% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-2.44 | Chg30d=-2.29% | Revisions=+20% | GrowthEPS=+0.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +20%